LGM Pharma Acquires Compounding Business Division From Zeta

LGM Pharma News

Erlanger, KY / Boca Raton, FL – LGM Pharma LLC today completed the acquisition of Zeta Pharmaceuticals’ compounding business. In Q4 2017, LGM received a significant growth capital investment from private equity firm, New Harbor Capital in Chicago. The acquisition of Zeta’s compounding business is a part of LGM’s strategy to invest in expanding its market presence and capabilities in an effort to better serve the pharmaceutical industry with a broad range of API and complementary services. The acquisition of Zeta will expand LGM Pharma’s current product offering within the compounding business segment, as well as strengthen its manufacturer relationships, enabling it to better support its customers.

Gideon Schurder, LGM Pharma’s commercial director stated: “With this Zeta acquisition we look forward to further streamlining our customers’ experience throughout all stages of the supply chain while providing expanded product offerings, enhanced warehousing and distribution centers for “just in time” door to door delivery as well as improved performance and technical capabilities. We believe that as the pharmacy industry is becoming more conscious of the need towards working with high quality and reputable API sources, LGM are uniquely positioned to provide even greater added-value to this business segment”.

Mendy Schurder, LGM Pharma’s COO stated: “In parallel with this acquisition, LGM is investing aggressively in its operational infrastructure through key additions to its senior management team, additional acquisitions and integration of sophisticated technologies & intelligence platforms; we look forward to sharing these developments with our customers as we move forward with this exciting growth agenda.”

“Zeta is comfortable knowing that LGM has built a very strong position and reputation in this segment of the pharmaceutical industry and will continue to provide excellent service and support to Zeta’s customers within this segment. LGM’s co-founders Mendy Schurder and Gideon Schurder have demonstrated a commitment to high quality, innovation and reliable service to its existing customers.” said Paul Harper, Zeta’s owner.

About LGM Pharma

LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies.

LGM specializes in streamlining API supply chain management throughout all development and commercial stages while providing complete technical capabilities, expert regulatory support, as well as other value-added services.

Related Posts

LGM Pharma Unveils Enhanced Analytical Testing Services and Expands CDMO Portfolio with Additional Suppository Manufacturing Capabilities
—50% expansion and over $2 million investment in standalone analytical testing services (ATS); offers...
Read More >
─CDMO Clinical and Commercial Manufacturing Services, Including Analytical Testing and Drug Product R&D...
Read More >
LGM pharma’s unique mix of API sourcing and CDMO services is fueling robust growth
─Customer Projects Bridging LGM Pharma’s API Sourcing and CDMO Services Range from Promising Pharmaceutical...
Read More >

Latest Posts